In a large, placebo-controlled trial, prophylactic omeprazole was associated with better self-reported pain-intensity and nonpain-symptom scores, although it had no effect on the rate of clinical dyspepsia.
Dual antiplatelet therapy (DAPT) with clopidogrel and low-dose aspirin is known to increase risk for gastrointestinal (GI) events. Previously, data from COGENT, a multinational, double-blind, double-dummy, placebo-controlled study, showed no adverse effects with addition of the proton-pump inhibitor (PPI) omeprazole but a significant reduction in GI adverse events (hazard ratio, 0.34; 95% confidence interval, 0.18–0.63; N Engl J Med 2010; 363:1909). Now, using results of the Severity of Dyspepsia Assessment questionnaire collected during COGENT, researchers have analyzed the effects of omeprazole on dyspepsia in patients taking DAPT. The questionnaire was used to assess symptoms in 3759 trial participants across three dimensions: abdominal-…
Reviewing Author
DisclosuresConsultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries
EquityCRH Medical Corporation
Editorial boardsMedscape Gastroenterology
Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors
DisclosuresConsultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries
EquityCRH Medical Corporation
Editorial boardsMedscape Gastroenterology
Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors